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Mycolic acids are major and specific lipid components of the mycobacterial cell envelope and are essential
for the survival of members of the genusMycobacterium that contains the causative agents of both tubercu-
losis and leprosy. In the alarming context of the emergence of multidrug-resistant, extremely drug-resistant,
and totally drug-resistant tuberculosis, understanding the biosynthesis of these critical determinants of the
mycobacterial physiology is an important goal to achieve, because it may open an avenue for the develop-
ment of novel antimycobacterial agents. This review focuses on the chemistry, structures, and known inhib-
itors of mycolic acids and describes progress in deciphering the mycolic acid biosynthetic pathway. The
functional and key biological roles of these molecules are also discussed, providing a historical perspective
in this dynamic area.Introduction
Mycolic acids (MAs), 2-alkyl, 3-hydroxy long-chain fatty acids
(FAs), are the hallmark of the cell envelope of Mycobacterium
tuberculosis and related species and genera (Daffe´ and Draper,
1998). They are found either unbound, extractable with organic
solvents such as esters of trehalose or glycerol, or esterifying
the terminal pentaarabinofuranosyl units of arabinogalactan
(AG), the polysaccharide that, together with peptidoglycan,
forms the insoluble cell wall skeleton (Daffe´, 1996; Daffe´ and
Draper, 1998; McNeil et al., 1991). Both forms presumably play
a crucial role in the remarkable architecture and impermeability
of the cell envelope, participating in the two leaflets of the myco-
bacterial outer membrane, also called the mycomembrane
(Figure 1), recently visualized by electron microscopy (Hoffmann
et al., 2008; Sani et al., 2010; Zuber et al., 2008). This concept
has been established inCorynebacterium glutamicum, a species
belonging to a genus that exhibits many features of the myco-
bacterial cell envelope (Daffe´, 2005), notably the presence of
an MA-containing outer membrane. Because Corynebacterium
strains are viable in the absence of MAs (Portevin et al., 2004,
2005), it has been proven that the outer membranewas no longer
observed in C. glutamicum mutant strains devoid of MAs (Hoff-
mann et al., 2008; Zuber et al., 2008). Because the inhibition of
MA synthesis is one of the primary effects of the frontline and
most efficient antitubercular drug isoniazid (INH) (Takayama
et al., 1972), much interest has been devoted to deciphering
the chemistry and biosynthesis of MAs. This metabolic pathway
represents a valuable source for recruiting potential targets for
the development of new antimycobacterial drugs in the alarm-
ing context of the emergence of multidrug-resistant (MDR),
extremely drug-resistant (XDR), and totally drug-resistant (TDR)
tuberculosis (TB). In addition, MA-containing compounds have
been associated in the past not only to many physiological prop-
erties of mycobacteria, such as their characteristic serpentine-
like growing and ‘‘cord-forming,’’ but also to numerous biological
properties, such as adjuvant and antineoplastic capacity of puri-
fied and crude cell wall fractions (Daffe´ and Draper, 1998; Goren
and Brennan, 1979; Verschoor et al., 2012).Chemistry & BiolThe last decade has seen impressive progress in the develop-
ment of the biochemistry, genetics, regulation, and structures of
MAs. Novel roles have also been attributed toMAs and their sub-
families in various phenomena, such as biofilm formation and
foamy macrophage (FM) formation in TB granulomas. This re-
view summarizes these studies, focusing on the biosynthetic
pathway and known inhibitors. It also describes some of the bio-
logical roles of these unique molecules.
Structure and Diversity of MAs
The first structures of MAs were described in 1950 (Asselineau
and Lederer, 1950) as long-chain FAs, two-branched, three-
hydroxylated, a feature that confers to the molecule the property
to be cleaved at high temperature, by a reaction similar to a
reverse Claisen-type condensation, into a ‘‘mero’’aldehyde
main chain, also called a ‘‘meromycolic chain,’’ and a ‘‘fatty
acid’’ (Table 1). MAs occur in all mycobacterial species exam-
ined to date. Structurally similar substances have been found,
with very few exceptions (e.g., Corynebacterium amycolatum
and Corynebacterium kroppenstedtii), in members of the order
Corynebacteriales. The stereochemistry of the centers at posi-
tions 2 and 3 has been shown to be conserved in all MA-contain-
ing genera, as 2R-, 3R- (Figure 2) (Asselineau and Asselineau,
1966; Asselineau et al., 1970b).
Elucidation of the MA structure has been addressed through
the application of combined analytical techniques, notably,
thin-layer chromatography (TLC), gas chromatography, high-
pressure liquid chromatography, mass spectrometry, and
nuclear magnetic resonance spectroscopy. Based on their
structural variability and complexity, MAs have been regarded
as genus- and species-specific compounds; consequently,
they were largely used as taxonomic markers. They consist of
chains of 22–38 carbon atoms in Corynebacterium, 30–36 in
Hoyosella and Amycolicicoccus, 34–38 in Dietzia, 34–52 in
Rhodococcus, 46–60 in Nocardia, 46–66 in Gordonia, 64–78
in Tsukamurella, 60–90 inMycobacterium, and up to 100 in Seg-
niliparus (Table 1). In addition, studies on the nature of the FAs
released by pyrolysis have been of a great interest in clarifyingogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 67
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Figure 1. Model of the Mycobacterial Cell Wall
The outer layer is mainly composed of glucan and proteins, with only a tiny amount of lipid. The mycomembrane corresponds to the permeability barrier. Its inner
leaflet is formed by a parallel arrangement of MA chains (in black) linked to AG that in turn is covalently attached to peptidoglycan (PG); the inner leaflet of the
mycomembrane is presumably composed of free lipids that include TDM (in red), TMM (in orange), various glycolipids (GL, in brown), and phospholipid (PL, in
blue). Adapted from Zuber et al. (2008). A representation of TDM shows the very-long chain of MAs that have to pack after folding at the site of the motifs (here
mycolic unit, cyclopropane, and keto group) to fit in a conventional membrane of 7–8 nm in thickness. The granular layer above the plasma membrane is
composed of proteins; these proteinsmay precipitate upon treatments of bacteria before the observation by transmission electronmicroscopy and yield a thicker
appearance to the outer leaflet of the plasma membrane (see Zuber et al., 2008).
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The lengths of these FAs consist in C8–C18 in Corynebacterium,
C12–C18 in Nocardia, and C22–C24 for most species of the
genus Mycobacterium, with the notable exception of the
M. tuberculosis complex and Mycobacterium xenopi where a
C26 occurs as the main homolog in their mycolates (Daffe´
et al., 1983) (Table 1).
Until recently, the structures of MAs of genera other than that
of mycobacteria were considered to be relatively simple in terms
of chemical functions, being composed only of a homologous
series with various numbers of double bonds, with up to six for
someTsukamurella species (Tomiyasu andYano, 1984) (Table 1).
In contrast, MAs of mycobacteria display a large diversity of
chain lengths and chemical functions that define the different
classes of MAs, leading to complex TLC patterns (Barry et al.,
1998; Daffe´ et al., 1983; Minnikin et al., 1983). The most apolar
MAs, referred to as a-MAs, contain 74–80 carbon atoms and
generally two double bonds (of cis- or trans-configuration) or
two cis-cyclopropyl groups located in the meromycolic chain
(Figure 2). A small fraction of a-MAsmay contain more unsatura-
tions, as observed in some strains of the M. tuberculosis com-
plex, with three unsaturations and longer chains (more than 6
to eight carbons) (Watanabe et al., 2001). Polyunsaturated
a-MAs were shown to represent a significant portion of the
MAs in Mycobacterium fallax (Rafidinarivo et al., 1985). MAs
with 60–62 carbon atoms, known as a’-MAs, contain one cis
double bond. Interestingly, the genus Segniliparus was recently
defined with a large array of MAs with chain lengths similar to
those ofmycobacteria and ranging from 60 to 100 carbon atoms,
composed of the C60–C62 a’- and C77–C79 a-MAs, and the novel,
extremely long-chain C90–C98 MAs, named a
+-MAs (Butler et al.,
2005; Hong et al., 2012; Lane´elle et al., 2013).68 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rIn addition, MAs from most mycobacteria examined so far
contain supplementary oxygen functions located in the distal
part of the meromycolic chain, defining the keto-, methoxy-,
wax ester-, epoxy-, and hydroxy-types of MA (Figure 2),
absent from a few mycobacterial species (Daffe´ et al., 1983)
and from genera of the order Corynebacteriales other than
mycobacteria, including the genus Segniliparus. The oxygen
functions occurring in mycobacterial MAs are typified by the
occurrence of an adjacent methyl branch. It is noteworthy that
in M. tuberculosis, the oxygenated MAs, i.e., keto-, methoxy-,
and hydroxy-MAs, contain 84–88 carbon atoms, and are thus
four to six carbons (even greater in minor components) longer
than the a-MAs from the same strains (Laval et al., 2001; Wata-
nabe et al., 2001). In contrast, the chain lengths of epoxy- and
wax ester-MAs found in nontuberculous mycobacterial species
are similar to those of a-mycolates of the same strains in which
keto-, methoxy-, and/or hydroxy-MAs have never been detected
(Laval et al., 2001).
MA Biosynthesis
The biosynthesis of mycobacterial FAs, precursors of MAs, is
achieved by at least two fatty acid synthases (FASs): (1) the
‘‘eukaryotic-like’’ multifunctional FAS-I produces FAs with a
bimodal distribution, C16–C18 and C24–C26 acids, with the latter
corresponding to the ‘‘a branch’’ found in MAs; and (2) the
‘‘bacterial-like’’ ‘‘dissociated’’ FAS-II, composed of a series of
discrete soluble enzymes (type-II system); this FAS is respon-
sible for the elongation of FAs at the origin of the very long mer-
omycolic chains. The Claisen condensation of the latter with the
a branch yields the characteristic 2-alkyl, 3-hydroxy (‘‘mycolic
motif’’) of MAs. Although the two FAS systems differ in their
molecular organizations, substrates, and carrier specificities,ights reserved
Table 1. MA Features in Different Genera of the Order Corynebacteriales
Genus or Species Total Carbon Mero-Chain FA Unsaturation Degreea Reference Kas Had
Corynebacterium 22–36 8–18 8–18 0–2 Collins et al., 1982 – –
Dietzia 34–38b 19:1 15–17b 0,1 Nishiuchi et al., 2000
Hoyosella 30–35b 20–25c 9–12b 0,1 Lane´elle et al., 2012 A A,B
Amycolicicoccus 30–36b 20–25c 9–12b 0,1 Lane´elle et al., 2012 A A,B
Rhodoccocus 30–54 12–16 0–2 Nishiuchi et al., 2000 A A,B
Rhodoccocus equi 30–50 14–34 14,16 0–2 Hsu et al., 2011 A A,B
Tomitella 42–52 Katayama et al., 2010
Smaragdicoccus 43–49 Adachi et al., 2007
Millisia 44–52 Soddell et al., 2006
Williamsia 50–56 16,18 Ka¨mpfer et al., 1999
Nocardia 46–60 32–40 12–18 0–3 Nishiuchi et al., 1999 A A,B fused
Skermania 58–64 42–48 16–20 2–6 Chun et al., 1997
Gordonia 46–66 16,18 1–4 Nishiuchi et al., 2000 A A,B fused
Tsukamurella 64–78 44–58 20:1,22:1 1–6 Tomiyasu and Yano,
1984
A A,B
Mycobacterium 60–90 42–62 22–26 1,2 (Barry et al., 1998 A,B A,B,C
Segniliparus 60–100 40–76 22,24 1–3 Hong et al., 2012;
Lane´elle et al., 2013
A,B A,B1,B2,C
MAs are characterized by their overall chain lengths and their pyrolysis products. Pyrolytic cleavage (p) at the C2–C3 carbon atoms releases a
meroaldehyde and a FA; R and R0 indicate long hydrocarbon chains.
aUnsaturation degree refers to the number of double bonds and/or cyclopropanes.
bMAs containing even and odd carbons were detected in these genera.
cThe (24:1), corresponding to C24 with one unsaturation, was identified as the major homolog. The occurrence of the FAS-II genes involved in the early
and late elongation steps of the mero-chain were searched in the available genomes (right): genes encoding the KasA and KasB (b-ketoacyl-ACP
synthase) and Had (b-hydroxyacyl-ACP dehydratase) activities are indicated; A, B and C are subunits of Had.
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reactions built on successive additions of a two-carbon (acetate)
unit from malonyl-coenzyme A (CoA) to a nascent acyl group
(Figure 3).
Malonyl-CoA is produced by the carboxylation of acetyl-
CoA, catalyzed by the acetyl-CoA carboxylase, a key enzyme
in most living organisms (Cronan and Waldrop, 2002). In myco-
bacteria, these enzymes display broad substrate specificities
(acetyl-CoA, propionyl-CoA, butyryl-CoA .) and are therefore
referred to as acyl-CoA carboxylases (ACCases) consisting of
multiple subunits containing at least a biotinylated a subunit
(AccA, including biotin carboxylase BC and biotin carboxyl car-
rier protein BCCP domains) and a b subunit (AccD, constituted
by the carboxyltransferase domain) (Diacovich et al., 2002;
Tong, 2005), the latter being responsible for the substrate
selectivity. M. tuberculosis displays an unusual number of
ACCases in its genome, with three a subunit genes (accA1–
accA3) and six ACCase carboxyltransferase domain genes
(accD1–accD6) and an epsilon subunit (accE, Rv3281) (GagoChemistry & Biolet al., 2006; Lin et al., 2006; Oh et al., 2006). Each ACCase,
which always comprises AccA3 (Rv3285), presumably serves
a different physiological role and provides various extender
units for the biosynthesis of the rich diversity of mycobacterial
FAs. The main physiological role of AccA3-AccD5 (Rv3280)
(epsilon dependent) would be to generate methylmalonyl-CoA
for the biosynthesis of multimethyl-branched FAs of the cell
envelope (Daffe´ and Draper, 1998) and to provide (accessory
role) malonyl-CoA as elongation unit for FA cycles (Oh et al.,
2006). This latter function would be preferentially achieved
by the AccA3-AccD6 (Rv2247) activity (epsilon inhibited) and
could thus play an important role in MA biosynthesis by
providing malonyl-CoA to the FAS-II complex (Gago et al.,
2011). The AccA3-AccD4 (Rv3799c) ACCase would be rather
dedicated to synthesize the carboxylated substrate (Portevin
et al., 2005) involved in MA condensation (Figure 3). Interest-
ingly, the accD4 (Rv3799c) gene is in operon with the genes
involved in the condensation reaction, pks13 (Rv3800c) and
fadD32 (Rv3801c).ogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 69
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Figure 2. Structural Characteristics of the MA Mero-Chains
(A) Structure of the a-dicyclopanated MA from M. tuberculosis. P and D indicate the proximal and distal positions, respectively, on the mero-chain where the
various motifs are found. The stereochemistry of the two conserved chiral centers, carbons 2 and 3, are R,R. Below are shown structures of the mero-chains of
representative types of MAs frommycobacteria. The configuration of double bonds and cyclopropanes is either cis or trans (with an adjacent methyl branch). The
established functions of the MTs are indicated. The stereochemistry of the asymmetric carbon atoms in the mero-chain is noted (S or R), i.e., carbon bearing
methyl, methoxyl, or hydroxyl groups.
(B) Reactions catalyzed bymycobacterial MTs and proposed reaction mechanisms (adapted from Lederer, 1969). The electrons p of the cis double bond attacks
the methyl group of S-adenosyl L-methionine to give a carbocation intermediate. Deprotonation steps catalyzed by a bicarbonate ion HCO3
 leads to the for-
mation of cis cyclopropane or to the methyl branch adjacent to the trans double bond. In the case of Hma, the bicarbonate ion is replaced by the side-chain
carboxylate of E146 that induced the deprotonation of a molecule of water. The activated water molecule OH in presence of the MT leads to the simultaneous
addition of the hydroxyl and the methyl on the carbocation intermediate. CPS, cylopropane synthase; Hma, hydroxy MA MT; UmaA1, unidentified MA MT.
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The mycobacterial FAS-I protein displays the seven distinct
domains corresponding to the catalytic activities required for
the synthesis cycle (Bloch and Vance, 1977; Fernandes and
Kolattukudy, 1996). Mycobacteria have a single FAS-I-encoding
gene (fas, Rv2524c), shown to be essential in Mycobacterium
smegmatis (Zimhony et al., 2004) and suggested to be essential
for M. tuberculosis growth based on high-density transposon
mutagenesis (Griffin et al., 2011). The FAs produced by FAS-I
are long-chain acyl-CoAs with a bimodal distribution, C16–C18
and C24–C26, a unique feature of themycobacterial FAS-I among
those of the order Corynebacteriales (Bloch and Vance, 1977;
Fernandes and Kolattukudy, 1996). The long-chain C24–C26
acyl-CoAs subsequently participate, after carboxylation by
ACCase, in MA biosynthesis (Figure 3).
Synthesis of the Meromycolic Backbone
Unlike the type-II synthases of other bacteria, the mycobacterial
FAS-II elongates C12–C16 FAs to yield C18–C30 acyl-acyl carrier
proteins (ACPs) in vitro, but it is incapable of de novo FA synthe-
sis from acetyl-CoA (Odriozola et al., 1977). The synthesis pro-
ceeds through the elongation of enzyme-bound intermediates,
covalently linked to mycobacterial acyl carrier protein (AcpM,70 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rRv2244), by several iterative cycles, each comprising four steps
(Bloch, 1977) (Figure 3).
The malonate group is transferred to ACP by malonyl-
CoA:ACP transacylase (MtFabD, Rv2243) to form malonyl-
ACP. FA synthesis is initiated by the Claisen condensation of
malonyl-ACP with acyl-CoA, catalyzed by b-ketoacyl-ACP syn-
thase III (MtFabH, Rv0533c), to form b-ketoacyl-ACP. Four
enzymes catalyze each cycle of elongation: the b-keto group is
reduced by the nicotinamide adenine dinucleotide phosphate-
dependent b-ketoacyl-ACP reductase (MabA, Rv1483), and
the resulting b-hydroxyl intermediate is dehydrated by the
heterodimer b-hydroxyacyl-ACP dehydratases (HadAB and
HadBC, Rv0635-Rv0636 and Rv0636-Rv0637, respectively) to
an enoyl-ACP. Next, the reduction of the enoyl chain by the
nicotinamide adenine dinucleotide hydrogen (NADH)-dependent
trans-2-enoyl-ACP reductase (InhA, Rv1484) produces an
acyl-ACP. Additional cycles of elongation are initiated by the
b-ketoacyl-ACP synthase (KasA or KasB, Rv2245 or Rv2246)
that elongates the acyl-ACP by two carbons to form a
b-ketoacyl-ACP. Elongation likely ceases when the acyl-ACP
attains the chain length required for meromycolic chain modifi-
cation or condensation. Although AcpM is hypothesized to beights reserved
(C24–C26) (C16–C18)
(C24–C26)
(C48–C62)
(C18–C32)
mycolic β-ketoester
(α branch)
Figure 3. Biosynthesis, Inhibition, and Regulation of Mycobacterial MAs
The biosynthetic pathway of MA starts with the de novo synthesis and elongation of FAs operated by themycobacterial FAS-I and FAS-II synthases, respectively.
The FAS-II synthase products undergo further elongation and modifications/decorations to produce the long mero-chain precursors. The carboxylation of acyl-
CoA (the FAS-I products) provides the alkylmalonate at the origin of the a branch. Condensation of the activated mero-chain with the alkylmalonate yields the
b-ketoester that, upon reduction, leads to the mature MA. The proteins shown to be regulated by Ser/Thr protein kinases are indicated by an asterisk (*). Known
inhibitors and the steps inhibited in the pathway are indicated (red): PYR, pyridomycin; NAS, NAS-21/NAS-91).
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evidence supports this hypothesis.
As expected from the essentiality of MA biosynthesis, InhA,
MabA, HadB, and KasA are essential proteins (Bhatt et al.,
2005; Brown et al., 2007; Parish et al., 2007; Sacco et al.,Chemistry & Biol2007; Vilche`ze et al., 2000). Neither HadA and HadC (our unpub-
lished results) nor KasB (Bhatt et al., 2007; Gao et al., 2003) is
essential. Even though KasA and KasB share significant
sequence similarity, they show different chain-length specific-
ities (Kremer et al., 2002; Schaeffer et al., 2001), suggesting aogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 71
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Reviewdistinct role for each enzyme. It has been shown that cell lysates
ofM. smegmatis expressingM. tuberculosis kasA could elongate
FAs up to 40 carbons, whereas the expression of both kasA
and kasB resulted in the production of longer chain FAs (54 car-
bons), equivalent to those of the meromycolate chains of MAs
(Slayden and Barry, 2002). Based on these in vitro biosynthesis
studies, it has been proposed that KasA is involved in the initial
elongation of MAs that are extended to their full lengths by
KasB (Kremer et al., 2002; Slayden and Barry, 2002). The kasB
mutants of both Mycobacterium marinum and M. tuberculosis
produce mycolates shorter by approximately two to four carbon
units, by up to six carbon atoms in the latter species, and they are
impaired in their growth, while exhibiting an increased perme-
ability of their cell walls and a severe defect in resisting host de-
fense mechanisms and antibiotic action (Bhatt et al., 2007; Gao
et al., 2003). Interestingly, the deletion of kasB inM. tuberculosis
is also accompanied by the loss of acid-fastness—the hallmark
trait of the tubercle bacilli. Moreover, thisM. tuberculosismutant
enters into a symbiotic state with immunocompetent mice,
causing a latent infection that may be important for the persis-
tence phenotype of tubercle bacilli (Bhatt et al., 2007). These
studies support the hypothesis that KasA is involved in initial
extension of the FAS-II-mediated growth of the MA chains,
whereas the dispensable KasB is implicated primarily in exten-
sion to full lengths. In addition to the elongation condensing en-
zymes, chain-length specificity is very likely dictated as well by
the two heterodimers of the b-hydroxyacyl-ACP dehydratases,
HadAB and HadBC, with HadB being the catalytic subunit and
HadA and HadC defining substrate selectivity for chain elonga-
tion. Thus, similarly to KasA, HadAB is most likely involved in
the early FA elongation cycles, whereas the HadBC heterodimer
is implicated in the late biosynthetic steps of the meromycolic
chain of mycobacteria (Marrakchi et al., 2008; Sacco et al.,
2007). This reasoning is supported by the distribution of the latter
proteins in members of the order Corynebacteriales (Table 1). In
genera producing very long-chain MAs, i.e., Amycolicicoccus,
Rhodococcus, Nocardia, and Gordonia, where the synthesis in-
volves elongation steps of the meromycolic chains, orthologs of
kasA and kasB and hadABC genes are detected in the genomes
(Lane´elle et al., 2012). Interestingly, in Segniliparus, a genus in
which the longest MAs are synthesized, the organizations of
both kasA/kasB and hadABC genes are different from those of
mycobacteria (Lane´elle et al., 2013). More surprising is the pres-
ence of two copies of hadB, the gene encoding the catalytic
domain of the dehydratase (Lane´elle et al., 2013). These obser-
vations reinforce the concept of implication of kas and had genes
in the elongation of the mero-chains of MAs.
Modification of the Meromycolic Chain
Introduction of Double Bonds
The presence of double bonds is observed in all MAs, from the
simplest C32–C34 corynomycolic acids to the most complex
mycobacterial MAs, and in the longest MAs ofSegniliparus. Little
is known about cis double-bond formation in MAs, except for
corynebacteria where unsaturated MAs are the result of the
condensation of two FAs with at least one molecule of oleic
acid (C18:1D9).
Several mechanisms have been proposed for the formation of
unsaturated FAs in other genera. Among these is the anaerobic72 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rdesaturation exemplified by Escherichia coli enzymes with the
b-hydroxydecanoyl ACP dehydratase (FabA) of FAS-II, a dehy-
dratase/isomerase enzyme able to catalyze not only the dehy-
dration of b-hydroxydecanoyl-ACP intermediate to give a trans
double bond but also the isomerization of the trans-2 double
bond into the cis-3 isomer. The cis-3-enoyl intermediate is sub-
sequently not reduced but further elongated by the b-ketoacyl-
ACP synthase I (FabB) to long-chain monounsaturated FAs,
thus diverting the nascent acyl-chain into the unsaturated FA
synthetic pathway (Marrakchi et al., 2002b; Rock and Cronan,
1996). Surprisingly, several groups of bacteria (including myco-
bacteria) lack both FabA and FabB enzymes, although they
synthesize unsaturated FAs and/or have an anaerobic meta-
bolism. This has led to the discovery in Streptococcus pneumo-
niae of the novel enzyme FabM, a trans-2-cis-3-enoyl-ACP
isomerase, in addition to the dehydratase (FabZ), able to divert
FA synthesis to the unsaturated mode (Marrakchi et al.,
2002a). Candidate proteins belonging to this superfamily exist
in the M. tuberculosis genome, namely, EchA10 and EchA11
(Takayama et al., 2005), and they may function in a FabM-like
manner, ensuring the isomerization of the trans-2 intermediate
produced in the FAS-II cycle (Figure 3) to the hypothetical cis-
3-enoyl FA, leading ultimately, after several elongation cycles,
to the formation of the cis double bond at the distal position of
the meromycolic chain (Bloch, 1969; Etemadi, 1967). However,
EchA10 and EchA11 are predicted to be nonessential (Griffin
et al., 2011). Because MAs are essential in mycobacteria, the
isomerization activity should be essential. Consequently, the
mycobacterial FabM-like candidates remain to be discovered.
As an alternative, an aerobic desaturation performed on a yet-
synthesized long chain and requiring both molecular oxygen and
NADH has been proposed. This is the process that leads to the
formation of oleic acid (C18:1D9) from stearic acid (C18:0) through
the action of the D9 desaturase. In mycobacteria this hypothesis
has been postulated for the formation of the cis double bond at
the distal position of the mero-chain of a-MAs. Considering the
structural similarity between the methyl terminus of the diethy-
lenic a-MAs and the C24 ethylenic FAs present in the bacteria,
a D5 desaturase operating on C24:0 to yield C24:1, followed by
elongation, was proposed (Asselineau et al., 1970a). This would
place the double bond at the expected distal position for the
a-mero-chain (Figure 2). Indeed, in various strains of mycobac-
teria, apart from the abundant oleic and palmitoleic (C16:1D9)
acids, the most frequently encountered FAs (such as C24 and
C26) are accompanied by their analogs with a cis double bond
in position 5,6 (Asselineau et al., 1970a). Analysis of the
M. tuberculosis genome reveals three potential aerobic desa-
turases encoded by desA1, desA2, and desA3 (Cole et al.,
1998). Overexpression of DesA3 in Mycobacterium bovis bacil-
lus Calmette-Gue´rin (BCG) and biochemical analysis of the puri-
fied enzyme showed that DesA3 (Rv3329c) is responsible for the
synthesis of oleic acid (Phetsuksiri et al., 2003). No function has
been yet defined for the proteins encoded by the two putative
desaturases DesA1 and DesA2. Among the possible desaturase
candidates is Rv1371. The protein displays expected character-
istics of membrane-bound acyl-lipid or acyl-CoA desaturases
and has been identified in culture filtrates of M. tuberculosis
and cell membrane fractions, but it exhibits only a weak similarity
to D5 desaturases.ights reserved
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teins, functionally similar to that recently identified in the group
of Cronan. FabQ possesses a dual dehydratase and isomerase
function and was identified in the saprophytic bacterium Aero-
coccus viridans. The protein allows the chain elongation by
progressive isomerization reactions to form polyunsaturated
FAs (Bi et al., 2013).
The possibility of the intervention of condensation enzymes
catalyzing the assembly of precursors by a series of successive
decarboxylation/condensation steps, as described for polyke-
tide synthases, also exists. The latter enzymes occur in myco-
bacteria, and their implication in the biosynthesis of specific
lipids of M. tuberculosis other than MAs, e.g., ‘‘phthiocerol and
companions,’’ has been demonstrated previously (Guilhot
et al., 2008; Kolattukudy et al., 1997). Based on structural and
labeling experiments, a head-to-tail condensation of palmitic
acid after an u-oxidation step has been proposed for nocardo-
mycolic acid, consistent with the double-bond location at u16
(Bordet and Michel, 1969; Tarnok and Ro¨hrscheidt, 1976). The
relationship between different types of MAs from mycobacteria
and the position of themotifs at similar intervals has led to the hy-
pothesis that the building of themero-chain could be the result of
condensation between three common FAs (C20, C16, and C22).
The position of double bonds or oxygenated groups would be
determined by the length of the FA precursor and by the faculta-
tive methylation (Asselineau et al., 2002). Is it noteworthy that
among the cis double-bond-containing mycolates, the shortest
a’-MAs, are remarkable in their invariable chain lengths of
C62:1–C64:1 (Figure 2), regardless of the species where they are
found, e.g., M. smegmatis, Mycobacterium abscessus, or the
new genus Segniliparus (Lane´elle et al., 2013). The fact that no
further modifications (cyclopropyl, methyl branch, oxygenated
functions) are observed in the a’-MAs suggests a distinct
pathway for their synthesis.
Insertion of Cyclopropyl and Methyl Groups
The introduction of all cyclopropanes and methyl branches
derives from methionine via S-adenosyl-methionine (SAM)
involving a cis double bond (Lederer, 1969). A family of
homologous (SAM)-dependent methyltransferases (MTs) that
share 50%–75% identity are present in the genome of
M. tuberculosis (Cole et al., 1998) and of sequencedmycobacte-
rial species, e.g.,M. bovis BCG,M. smegmatis, andMycobacte-
rium leprae. Among these MTs, the cyclopropane synthases
(CPSs) of M. tuberculosis share 30%–35% identity with that of
E. coli that catalyzes the addition of a methyl group to a double
bond. Four of the eight MTs identified inM. tuberculosis, namely,
CmaA1, CmaA2, PcaA (formerly UmaA2), and MmaA2, display
strong sequence similarities with the E. coli CPS, suggesting a
common reaction mechanism (Figure 2B). Inactivation experi-
ments of the M. tuberculosis MT genes have established their
respective functions (Figure 2) and corrected some false
interpretations concluded from protein overexpression experi-
ments. For instance, deletion of the umaA2 (for unknownmycolic
acid MT) gene has shown that the encoded protein is respon-
sible for the formation of the proximal cis-cyclopropane of
M. tuberculosis a-MA. This gene was thus renamed pcaA (for
proximal cyclopropanation of alpha-MAs) (Glickman et al.,
2000) (Figure 2). This function was previously attributed to
cmaA2 (for cyclopropanation of mycolic acids) by overexpres-Chemistry & Biolsion of the encoded protein in M. smegmatis (George et al.,
1995). Knockout (KO) of cmaA2 inM. tuberculosis has impacted
only the structures of oxygenatedMAs (methoxy- and keto-MAs)
of the strain that contained double bonds instead of the proximal
trans-cyclopropane rings (Glickman et al., 2001). Similarly, the
overexpression of M. tuberculosis CmaA1 led to the conclusion
that this MT introduces the cis-cyclopropane at the distal posi-
tion in a-MAs (Yuan et al., 1995), a conclusion subsequently con-
tradicted by the analysis of a cmaA1 null mutant, indicating that
CmaA1 is not required for the distal cis-cyclopropanation of the
a-MAs (Glickman, 2003). These genetic and biochemical studies
have led to important advances in the understanding of how
cyclopropanes are introduced on the meromycolic chain and
enabled to assign a role to many, if not all, of the different
CPS-type MA-MTs (Figure 2).
Numerous questions are still pending, especially regarding
the specific MA-MTs responsible for introducing methyl
groups at the proximal position and adjacent to trans-cyclopro-
panes in the oxygenated MAs of the M. tuberculosis complex
species and to double bonds in the a- and epoxy-MAs of
M. smegmatis (Figure 2). For instance, the M. tuberculosis
umaA1 (umaA, Rv0469) KO mutant exhibited no change in the
MA profile despite the hypervirulence phenotype observed
in the SCID mouse infection model, pointing to a specific
impact of the mutation in an in vivo context (Laval et al., 2008).
In contrast, the inactivation of the orthologous gene in
M. smegmatis (MSMEG_0913) resulted in the abolition of the
synthesis of subtypes of MAs containing a methyl branch adja-
cent to either trans-cyclopropyl group or trans double bond at
the proximal position of both a- and epoxy-MAs (Laval et al.,
2008) (Figure 2).
The crystal structures of several MTs from M. tuberculosis
have been solved and compared with one another (Huang
et al., 2002). Interestingly, a bicarbonate ion is conserved in all
proteins that catalyze the cyclopropanation reaction (CmaA1,
CmaA2, MmaA2, and PcaA), in contrast to the MTs involved in
the formation of oxygen-containing groups (MmaA3 and
MmaA4). The three-dimensional structures thus support the
hypothesis that these CPS enzymes catalyze methyl transfer
via a carbocation mechanism in which the bicarbonate ion acts
as a general base (Figure 2B), as demonstrated for E. coli CPS
(Courtois and Ploux, 2005; Huang et al., 2002). What defines
the action of the MT enzymes on distal versus proximal parts
of the acyl chain is still enigmatic, but the idea of substrate spec-
ificity dictated by different lengths of the substrate-binding cavity
is an attractive hypothesis.
Introduction of Oxygenated Functions
The biosynthesis of both keto- andmethoxy-MAs, two classes of
MAs found in members of the M. tuberculosis complex and
selective slow growers, is intimately linked to that of the common
hydroxymycolate precursor that is catalyzed by the MT Hma
(MmaA4), a SAM-dependent enzyme. The hmamutant no longer
produced keto- or methoxy-MAs (Dubnau et al., 2000), while still
able to synthesize a-MAs having two cyclopropanes (as found in
the parent strain), and displaying a novel a-mycolate type
bearing a cis double bond in the distal position and a cis-cyclo-
propane in the proximal part of the molecule (Dinadayala et al.,
2003). The presence and precise position of this distal double
bond have led to postulate this ethylenic mycolate as theogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 73
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presence of a water molecule, would methylate the cis double
bond and catalyze a concerted hydroxylation. The hydroxylated
intermediate at the branch point would then give either the keto-
or the methoxy-MAs, the latter resulting from the action of the
‘‘methoxylase’’ MmaA3 (Dinadayala et al., 2003; Dubnau et al.,
1997, 1998, 2000; Yuan and Barry, 1996; Yuan et al., 1998)
(Figure 2). Because the newly synthesized a-mycolate in the
hma mutant is shorter by four to six carbon atoms than the
keto- and methoxy-MAs of the wild-type strain, the key reaction
on the ethylenic molecule would occur earlier, at the ‘‘meromy-
colate’’ stage.
The three-dimensional structures of Hma (Boissier et al.,
2006), interestingly, point to some differences with those of the
three CPS-type MA SAM-MTs previously crystallized (Huang
et al., 2002). The bicarbonate ion found in the active site of the
CPSs is absent in Hma. Instead, in the superimposed structures,
the side-chain carboxylate of glutamate 146 (E146) is placed at
exactly the same position as the bicarbonate in CPSs. It was
thus tentatively proposed that the carboxylate of the E146 might
function as a general base to activate a water molecule for a
nucleophilic attack (Figure 2B) (Boissier et al., 2006). As originally
proposed by Lederer (1969), it is tempting to state that the catal-
ysis by MA-MTs would follow the same route to the carbocation
intermediate and then differ in the second step, leading to either
cyclopropaned, methyl-branched, or hydroxylated MAs with an
adjacent methyl branch (Figure 2B). As an alternative, Hma
would catalyze the introduction of themethyl group on a strongly
nucleophilic site, such as a b-ketoester generated from a con-
densation reaction (Asselineau et al., 2002; Dinadayala et al.,
2003; Lederer, 1969). The characterization of small amounts of
an epoxymycolic acid devoid of an adjacent methyl branch in
the hma-deleted mutant strain would represent a putative candi-
date for such methylation (Dinadayala et al., 2003).
The genes encoding the proteins involved in the biosynthesis
of other oxygenated functions such as wax-, epoxy-, and u-1
methoxylated MAs (Figure 2A) remain to be discovered. Never-
theless, from structural data, it is possible to formulate a few
hypotheses. The wax-mycolates have been shown to derive
from the keto-MAs by Baeyer-Villiger oxidation that involves
the insertion of molecular oxygen, thus converting the ketone
to the corresponding ester (Toriyama et al., 1982), as postu-
lated previously (Etemadi and Gasche, 1965; Lane´elle and
Lane´elle, 1970). Flavin-containing Baeyer-Villiger monooxyge-
nases (BVMOs) are known for using NADH/NADPH and molecu-
lar oxygen for degradation of toxic ketones. Such enzymes are
present in mycobacteria, e.g., EthA (Rv3854c) that accepts a
ketone as substrate and has been shown to activate the anti-
TB prodrug ethionamide (ETH) to its active form (Fraaije et al.,
2004). Six additional genes encoding BVMOs are present in
the M. tuberculosis genome. Although ETH has been shown to
inhibit the synthesis of oxygenated MAs in Mycobacterium
aurum, a keto- and wax-MA-containing species (Que´mard
et al., 1992), the annotated genes are not likely to encode the
enzymes involved in the oxidation of keto- into wax-MAs by a
process of Baeyer-Villiger oxidation because M. tuberculosis
strains are devoid of wax-MAs.
From structural analyses, notably the chain length and stereo-
chemistry of the asymmetric carbons bearing both the methyl74 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rbranches adjacent to the oxygenated functions (Daffe´ et al.,
1981; Lacave et al., 1987; Minnikin et al., 1982), it clearly appears
that no structural relationship can be established between the
epoxy- and the keto-MAs. In contrast, it is reasonable to postu-
late that the formation of epoxy-MAs could result from the
transformation of an a-mycolate-type intermediate having a
trans double bond at the distal position with an adjacent methyl
branch (Figure 2).
The u-1 position of the methoxy group found in a class of MAs
(Figure 2) raises a newquestion. Because nomethyl branch adja-
cent to the oxygen function is found in this compound, it is
tempting to speculate that the precursor of such product could
be an intermediate with a terminal double bond rather than the
result of a MmaA3/MmaA4-like process. In this respect, it is
interesting to mention that a careful analysis of MAs from
M. smegmatis had shown the presence of minor amounts of
MAs with a terminal double bond (Wong and Gray, 1979).
Furthermore,M. smegmatiswas shown to performu-1 oxidation
of hydrocarbons (Rehm and Reiff, 1981).
MA Condensation and Transfer
The MA synthesis involves, in addition to FAS-I and FAS-II, a
condensation reaction between two activated FAs, a penulti-
mate and key step leading to the formation of the ‘‘mycolic
motif.’’ The formation of a new carbon-carbon bond by a Claisen
condensation is a reaction shared by both FA and polyketide
synthase biosyntheses and is catalyzed by condensing enzymes
or condensases (Heath and Rock, 2002).
Condensation Enzymes
Despite extensive efforts in several laboratories, the conden-
sase responsible for the synthesis of MAs has remained a
mystery for more than 50 years. Given the importance and
specificity of this final step, a condensase candidate must be
present in all Corynebacteriales and conserved in M. leprae,
the genome of which has a large number of pseudogenes.
The polyketide synthase 13 (Pks13), a member of the type-I
Pks family, was identified as the enzyme responsible for the final
construction of MAs in both C. glutamicum and M. smegmatis
(Portevin et al., 2004). The discovery of the condensase for
MA synthesis probably illustrates the remarkable benefit of
using the Corynebacterium model for exploring the more com-
plex Mycobacterium MA biosynthetic pathway. More than 18
type-I pks genes are present in the M. tuberculosis genome
(Cole et al., 1998). However, the search of the Corynebacterium
diphtheriae and C. glutamicum genomes revealed the occur-
rence of a single pks gene conserved in all Corynebacteriales
species analyzed, leading to the identification of Pks13 as the
condensing enzyme (Portevin et al., 2004). In C. glutamicum,
the inactivation of the pks13 gene abolishes the production of
MAs, thus altering the mycomembrane (Portevin et al., 2004)
and the structure of the envelope (Hoffmann et al., 2008; Zuber
et al., 2008). Pks13 is a protein displaying five distinct domains
corresponding to the catalytic activities required for condensa-
tion: peptidyl carrier protein (PCP)-like domain, ketoacyl syn-
thase (KS), acyl transferase (AT), ACP domain, and thioesterase
(TE). To be activated, Pks13 needs a posttranslational modifica-
tion, catalyzed by the mycobacterial 40-phosphopantetheinyl
transferase PptT, essential for activation of the ACP and PCP
domains (Chalut et al., 2006).ights reserved
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also several enzymes involved in the activation of the two
condensase substrates. Specifically, activation of the ‘‘meromy-
colic’’ chain (through the action of an acyl-adenylate [acyl-AMP]
ligase) and carboxylation of the a branch (by an acyl-CoA
carboxylase) are essential for the formation of MAs in Coryne-
bacterium and Mycobacterium (Gande et al., 2004; Portevin
et al., 2004; Portevin et al., 2005) (Figure 3). The fadD32 gene
(Rv3801c) is adjacent to pks13 (Rv3800c), and this genetic orga-
nization fadD32-pks13 is conserved in M. tuberculosis and
M. leprae and was among the hints suggesting the involvement
of the fadD32-encoded protein in the condensation reaction.
FadD32 catalyzes the production from free FA of acyl-AMP (Triv-
edi et al., 2004) (Figure 3). Like fadD32, some of the 34 fadD are
adjacent to pks genes on theM. tuberculosis genome and, inter-
estingly, were found to encode fatty acyl-AMP ligases rather
than having a fatty acyl-CoA ligase activity (Trivedi et al., 2004).
These proteins activate long-chain FAs as acyl-adenylates that
are then transferred to the multifunctional Pks for further chain
extension. FadD32 acts in concert with Pks13 and activates
the very-long meromycolic acid (C50–C60) before its condensa-
tion with a C24–C26 FA (Gavalda et al., 2009; Le´ger et al., 2009).
The involvement of the AccD4 carboxyltransferase in MA syn-
thesis (Gande et al., 2004; Portevin et al., 2005) and its essenti-
ality for mycobacterial survival have been demonstrated by
inactivation of the fadD32 gene, resulting in the lack of produc-
tion of MA (Portevin et al., 2005). The fact that a fadD32-KO
mutation in C. glutamicum, which abolishes the synthesis of
one of the activated partners for condensation (acyl-AMP), also
led to the accumulation of the second condensation substrate
(tetradecyl malonic acid) (Portevin et al., 2005) clearly proves
that a carboxylation step, leading to the formation of a malonyl
derivative, takes place before the condensation reaction occurs
in MA biosynthesis. An alkyl-malonyl intermediate is also formed
in a C. glutamicum mutant deficient in the synthesis of Pks13,
indicating that carboxylation of the a branch chain occurs most
likely before the transfer onto the condensase Pks13 (Portevin
et al., 2005). The unique specificity of AccD4 for the C24–C26
long chains is in agreement with the a branch lengths being of
24–26 carbons in mycobacteria and confirms the role of AccD4
in MA condensation (Oh et al., 2006).
Formation of Mature MAs and Their Transfer
Upon condensation, the product of Pks13 is the mycolic
b-ketoester that needs to be reduced to produce the mature
mycolate (Figure 3). In corynebacteria, it has been shown that
a b-ketoester of trehalose was detected in the first minute of
corynomycolic acid synthesis, pointing to the importance of
trehalose in the metabolism of these acids (Ahibo-Coffy et al.,
1978; Tropis et al., 2005; Walker et al., 1973). The enzyme cata-
lyzing the reduction of the b-ketoester was identified by inactiva-
tion experiments of the candidate NCgl2385 gene, the ortholog
ofRv2509 (cmrA) inM. tuberculosis, inC. glutamicum (Lea-Smith
et al., 2007). The resulting mutant still synthesizes b-ketoester of
both trehalose and AG (in lower amounts) but was deficient
in AG-linked mature mycolates. Likewise, inactivation of the
M. smegmatis ortholog of cmrA (MSMEG_4722) resulted in the
loss of mature MAs linked to the cell wall AG, yet retained
the production of b-ketoesters of AG and trehalose (Bhatt
et al., 2008). The latter products are also synthesized by theChemistry & Biolpurified Pks13 protein, provided that FadD32 and both free
and carboxylated FAs are present in the in vitro reaction mixture
(S. Gavalda, F. Bardou, M. Daffe´, and A. Que´mard, unpublished
data). The transfer of the mycoloyl residues onto the cell wall AG
acceptors occurs virtually by the mycobacterial fibronectin-
binding proteins that have been shown to possess the mycoloyl
transferase activity in vitro (Belisle et al., 1997) and in vivo (Puech
et al., 2000, 2002).
MA Elongation Complexes
Based on the genetic and biochemical interaction experiments
between the various FAS-II components, our group has pro-
posed a working model in which different specialized FAS-II
complexes would be interconnected (Veyron-Churlet et al.,
2004, 2005) and interact with MA-MTs (Cantaloube et al.,
2011). This model predicts the occurrence of at least three
(specialized) FAS-II complexes involved in MA synthesis, with
each complex being constituted by a ‘‘FAS-II core’’ (formed by
InhA, MabA, and MtFabD) associated to a specific condensing
(Kas) enzyme and dehydratase (Had) heterodimers, thus defining
their substrate specificity. An ‘‘initiation’’ FAS-II complex, con-
taining mtFabH, might allow the channeling of acyl-CoA from
FAS-I to FAS-II during their condensation with malonyl-ACP
(Figure 3). This step would be followed by a type-I ‘‘elongation’’
complex formed by the core proteins and KasA that would
elongate medium-length acyl-ACP chains that could serve as
substrates for a type-II elongation complex (E2-FAS-II). The
latter, comprising the core and KasB, could end the synthesis
of the meromycolic chain. This end product of E2-FAS-II may
be used in the terminal condensation reaction catalyzed by
Pks13, which is assumed to be part of a ‘‘termination’’ FAS-II
complex.
MA Biosynthesis Regulation
Membrane lipid biogenesis is a vital facet of mycobacterial phys-
iology that must be tightly regulated at both the genetic and
biochemical level. M. tuberculosis also produces an impressive
array of complex bioactive lipids that are intimately involved in
pathogenesis and protective immunity. Mycobacterial survival
depends on membrane lipid homeostasis and on the ability to
adjust lipid composition to adapt the bacterial cell to optimize
growth in the prevailing conditions it faces in vivo. FA and
MA acyl chains determine the viscosity of the membrane
that in turn influences many crucial membrane-associated
functions. Many sophisticated regulatory strategies used by
M. tuberculosis to finely control cell wall biosynthesis have
now been elucidated (Dover et al., 2007b). In particular, myco-
bacteria control the expression of the genes responsible for
the metabolism of MAs by adjusting the level and activity of
biosynthetic enzymes to match the demand for new membrane
synthesis and extension of its complex cell wall. These mecha-
nisms are only starting to be understood.
The transcriptional regulator MabR (Rv2242) functions as a
repressor in M. tuberculosis to control the expression of essen-
tial genes involved in MA biosynthesis (Salzman et al., 2010) by
repressing the fabD-acpM-kasA-kasB gene cluster and affecting
the expression of fas that encodes the multifunctional FA syn-
thase FAS-I. Overexpression of MabR represses transcription
and inhibits MA synthesis. The mabR gene is likely essential inogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 75
Chemistry & Biology
ReviewM. tuberculosis (Sassetti et al., 2001). This hypothesis is further
supported by the demonstration that the chromosomal copy of
M. smegmatis mabR could only be disrupted in the presence
of a wild-type copy of the gene provided in trans (Salzman
et al., 2010).
The activities of key enzymes in MA synthesis are also modu-
lated at posttranslational levels, as are many metabolic pro-
cesses in M. tuberculosis regulated by Ser/Thr protein kinases
(STPKs)-mediated phosphorylation. In fact, a growing body of
evidence suggests that Ser/Thr phosphorylation play important
roles in the physiology and virulence of M. tuberculosis.
Recently, the importance of protein phosphorylation networks
in cell wall biosynthesis has attracted considerable interest.
An array of two-component and eukaryotic-like STPK systems
has been discovered, and several are implicated in central meta-
bolic processes, cell division, and cell wall biogenesis. Compre-
hensive reviews on structure-function studies of Ser/Thr and Tyr
protein phosphorylation have been published previously (Av-
Gay and Everett, 2000; Greenstein et al., 2005; Wehenkel
et al., 2008). The pathogen uses ‘‘eukaryotic-like’’ STPKs and
phosphatases to regulate many intracellular metabolic pro-
cesses, including MA biosynthesis. In this pathway, many pro-
teins were identified as substrates for the STPKs (Figure 3),
and their phosphorylation was found tomodulate their enzymatic
activity to control MA synthesis (Bhatt et al., 2007; Molle and
Kremer, 2010). Phosphorylation of essential enzymes of the
M. tuberculosis FAS-II system, KasA, InhA, and MabA, and the
dehydratases HadAB and HadBC was found to downregulate
their respective activities. Similarly, phosphorylation of the
mycobacterial PcaA inhibits MA cyclopropanation, thus modu-
lating intracellular survival of mycobacteria (Corrales et al.,
2012). The proportion of phosphorylated HadAB and HadBC
clearly increases at the stationary growth phase, suggesting
that mycobacteria shut down meromycolic acid chain produc-
tion in the stationary phase (Slama et al., 2011). The differential
expression of the mycobacterial STPKs in response to stress
conditions might directly affect the phosphorylation profile of
these substrates and as a consequence modulate MA biosyn-
thesis to promote adaptation to environmental changes.
MA Inhibition and Antituberculous Drug Discovery
The rise in antibiotic-resistant M. tuberculosis and the relatively
few candidates in the drug development pipeline for TB highlight
the urgent need for novel anti-TB agents, ideally with mecha-
nisms of action different from those of existing drugs and effi-
cient on MDR, XDR, and TDR isolates. Recent years have seen
an enormous increase in efforts to discover new lead com-
pounds using both whole-cell screening and target-based
biochemical approaches, although progress in validating new
targets has been slower than expected. Many efforts currently
focus on revisiting and optimizing existing inhibitors (of validated
targets in FAS-II.) through rational drug design and structure-
activity relationship studies.
The unique cell envelope lipids produced by M. tuberculosis
play essential roles in the physiology and pathogenicity of these
bacteria (Daffe´ and Draper, 1998). As such, the MA biosynthetic
pathway is a validated site of action of many of the current first-
and second-line anti-TB drugs (Figure 3) and therefore has
significant potential as a target for the development of novel anti-76 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rmycobacterial drugs (Jackson et al., 2013), particularly because
targeting new steps in well-validated biosynthetic pathways in
antitubercular therapy is a powerful strategy that removes
much of the usual uncertainty surrounding new targets and
in vivo clinical efficacy.
FA Synthesis and Elongation Inhibitors
Acyl-CoA Carboxylase Inhibition. Acetyl-CoA carboxylases have
crucial roles in FA metabolism (see above) and are attractive tar-
gets for drug discovery (Gago et al., 2011). In an effort to find in-
hibitors of the M. tuberculosis ACCases, the crystal structure of
AccD5 (Lin et al., 2006) has been solved, and structure-based
in silico screening has been performed as described previously
(Chen et al., 2005). AccD5 inhibitors have been identified and
assayed in vitro for inhibition of AccD5 and for the whole
AccA3-AccD5 enzyme complex. Given the conserved structure
of the AccD5 and AccD6 active sites, several inhibitors of
AccD5 have been also screened as potential inhibitors of
AccD6, leading to ligand NCI-172033 (NCI) that is capable of in-
hibiting AccD6 (Kurth et al., 2009). This compound also has
shown bactericidal activity against several pathogenic myco-
bacteria by causing a strong inhibition of both FA andMAbiosyn-
thesis. Overexpression of AccD6 inM. smegmatis has conferred
resistance to NCI, confirming that AccD6 is themain target of the
inhibitor and a good target for the development of new antimyco-
bacterial agents (Kurth et al., 2009) (Figure 3).
b-Ketoacyl-ACP Synthase Inhibition. The fact that several
natural products target the elongation step in FA biosynthesis
clearly emphasizes the condensing enzymes as desirable tar-
gets for drug development (Heath and Rock, 2004). Cerulenin
(produced by Cephalosporium caerulens) irreversibly inhibits
FAS from a variety of organisms (Price et al., 2001). It inhibits
both KasA and KasB activity (Kremer et al., 2002; Schaeffer
et al., 2001). However, although some therapeutic efficacy has
been shown in models of yeast infection, cerulenin also inhibits
eukaryotic FAS and has not been pursued as a lead for novel
antimicrobials. More interest has been driven toward the natural
molecule produced by Nocardia, thiolactomycin (TLM), that is
specific for type-II synthases and exhibits broad activity toward
Gram-negative and Gram-positive bacteria, and toward impor-
tant pathogens, including Plasmodium falciparum andM. tuber-
culosis (Kremer et al., 2000). TLM, composed of a thiolactone
ring, binds to the malonate portion of the active site of the
condensing enzyme. The drug targets both M. tuberculosis
KasA and KasB, binding preferentially to the KasA acyl-enzyme
with low micromolar affinity (Machutta et al., 2010). Designed
analogs of TLM with longer chains are better inhibitors of the
mycobacterial KasA and KasB enzymes. TLM was shown to
inhibit MA biosynthesis in vitro and retains good antimycobacte-
rial activity in vivo (Douglas et al., 2002).
Recent efforts are being directed toward improving the affinity
of TLM for KasA and developing chemical tools to investigate the
substrate binding and catalytic mechanism of KasA through
design and synthesis of classes of substituted TLM-derivatives
with structural features reminiscent of either the acyl- or the
malonyl-AcpM substrates of the enzyme (Kapilashrami et al.,
2013).
Enoyl Reductase Inhibition. The M. tuberculosis enoyl-ACP
reductase InhA has been demonstrated to be the target of
both INH and ETH, validating it as a remarkable antitubercularights reserved
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ally simplest drugs, was found to have an exquisite activity
against M. tuberculosis more than 50 years ago, yet its precise
mechanism of action could not be elucidated until genetic tools
were developed in M. tuberculosis. The combination of genetic,
biochemical, and X-ray crystallographic studies (Banerjee et al.,
1994; Dessen et al., 1995; Rozwarski et al., 1998) provided a
consistent model indicating that INH is activated by the cata-
lase-peroxidase KatG to form an adduct with nicotinamide
adenine dinucleotide (NAD) that inhibits the inhA-encoded
NADH-dependent enoyl-ACP reductase of FAS-II (Figure 3).
Likewise, ETH is a prodrug and is activated in M. tuberculosis
by EthA, a flavin monooxygenase, to form a covalent ETH-NAD
adduct that inhibits InhA (Morlock et al., 2003; Wang et al.,
2007). Expectedly, inhibition of InhA leads to inhibition of MA
biosynthesis, accumulation of long-chain FAs (Takayama et al.,
1975; Winder and Collins, 1970), and ultimately to cell death
(Vilche`ze et al., 2000; Wang et al., 2007). INH and ETH are highly
specific and effective, and being prodrugs, mutations in the
activators KatG and EthA have been correlated to most of the
clinical resistance in the cases of drug-resistant TB (Hazbo´n
et al., 2006; Morlock et al., 2003).
The search for compounds that do not require activation and
that directly target InhA represents a promising approach to
circumvent this resistance mechanism (Freundlich et al., 2009).
In this context, the broad-spectrum antimicrobial triclosan
(TRC) inhibits InhA without needing activation, although its use
as an antitubercular may be limited by its suboptimal bioavail-
ability (Kuo et al., 2003). Using a structure-based drug design
approach, a series of substituted triclosan derivatives have
been developed, and compounds were identified with dramati-
cally enhanced potency against purified InhA, with some up to
50-fold more potent than triclosan. X-ray crystal structures of
InhA in complex with triclosan derivatives revealed the structural
basis for the inhibitory activity, and selected triclosan derivatives
have been tested against INH-sensitive and -resistant strains of
M. tuberculosis. Among those, the best inhibitor had a bacteri-
cidal activity 10-fold lower than that of triclosan. A subset of
these triclosan analogs were more potent than INH against
INH-resistant M. tuberculosis strains, demonstrating the signifi-
cant potential of structure-based design in the development of
next generation antitubercular drugs (Freundlich et al., 2009).
The natural product pyridomycin (PYR), first described in 1953
with specificity toward mycobacteria (Maeda et al., 1953), was
also found to target InhA and to inhibit MA synthesis in
M. tuberculosis (Hartkoorn et al., 2012). Interestingly, the most
frequently encountered INH-resistant clinical isolates are fully
susceptible to PYR, thus opening promising avenues for the
treatment of INH-resistant tubercle bacilli.
Dehydratase Inhibition. Isoxyl (ISO) and thiacetazone (TAC),
once used in the clinical treatment of TB, are prodrugs that
have to be activated by the mycobacterial monooxygenase
EthA (Dover et al., 2007a). They have dramatic effects on MA
biosynthesis, consistent with both drugs inhibiting an early and
essential step of the pathway, e.g., the elongation of the main
(meromycolate) chain by FAS-II (Figure 3). A combination of
genetic and biochemical approaches identified the precise steps
of the biosynthetic pathway interrupted by these two prodrugs
to be the dehydratase step, catalyzed by the b-hydroxyacyl-Chemistry & BiolACP dehydratases (encoded by the hadABC genes) of the
FAS-II elongation system (Belardinelli and Morbidoni, 2012;
Coxon et al., 2013; Grzegorzewicz et al., 2012a). Both com-
pounds are the first clinically used anti-TB drugs reported to
act at the dehydration step. Consistent with their mode of action
and similarly to INH, ISO and TAC display bactericidal activity on
actively replicating M. tuberculosis in vitro.
The antimalarial phenylsulfanylmethyl-[1,4]-naphthoquinones
NAS-21 and NAS-91, first identified as inhibitors of the b-hydrox-
yacyl-ACP dehydratase FabZ of P. falciparum (Sharma et al.,
2013), were found to exhibit potent antimycobacterial activity,
with NAS-91 being more active than NAS-21 (Gratraud et al.,
2008). Synthesis of NAS analogs and evaluation of their whole-
cell activity against M. bovis BCG allowed for determination of
their activity against FAS-II but not FAS-I synthesis in vitro, impli-
cating in particular Rv0636 (HadB) as the candidate target of
these inhibitors (Bhowruth et al., 2008).
MA Condensation and Transport Inhibitors
Targeting unique steps inMA pathway already inhibited by a cur-
rent antibiotic, e.g., INH, is an effective strategy for anti-TB drug
discovery by potentially bypassing existing resistance to current
pathway inhibitors, especially in the context of MDR, XDR, and
TDR TB. This is particularly illustrated by the recent identification
of inhibitors of the (essential and validated) mycolic condensa-
tion enzymes Pks13/FadD32 and the enzymes for MA transloca-
tion and transfer MmpL3/Ag85 (Figure 3).
The operon fadD32-pks13-accD4 is essential for the viability of
mycobacteria (Portevin et al., 2004, 2005) and was established
both as a vulnerable target (Carroll et al., 2011) and a ‘‘drug-
gable’’ target (Galandrin et al., 2013). The 4,6-diaryl-5,7-dimethyl
coumarins (CCAs), with the most potent CCA34 compound,
were shown to kill M. tuberculosis by inhibiting FadD32 activity
and effectively blocking bacterial replication in vitro and in animal
models of TB (Stanley et al., 2013).
The discovery and validation of Pks13 as the key condensing
enzyme required in MA synthesis (Gavalda et al., 2009; Portevin
et al., 2004) have brought this protein to the forefront as an
attractive and essential drug target. Thiophene (TP) compounds
that interfere with the function of the N-terminal ACP domain of
Pks13 have been identified; they inhibit both the activity of the
protein and MA synthesis, leading to mycobacterial cell death
(Wilson et al., 2013). ‘‘Compound 3,’’ identified by combining
high-throughput screening (HTS) with whole-genome sequenc-
ing (WGS) of resistant isolates, kills mycobacterial cells, likely
through interferencewith the TE activity in the C-terminal domain
of Pks13 (Ioerger et al., 2013).
The above-mentioned HTS campaign withWGS (Ioerger et al.,
2013) has identified ‘‘compound 2’’ as a promising drug that
inhibits the inner membrane transporter MmpL3 (Rv0206c).
This protein is also targeted by several inhibitors, among which
are the anti-TB pyrrole derivative BM212 (La Rosa et al., 2012);
a novel urea derivative AU1235 [1-(2-adamantyl)-3-(2,3,4-
trifluorophenyl)urea] (Grzegorzewicz et al., 2012b); and the
anti-TB drug SQ109 (Tahlan et al., 2012); the latter compounds
abolished the translocation of trehalose monomycolates
(TMMs) from their cytoplasmic or membrane-associated site of
production to the periplasm where they can then be transferred
onto arabinogalactan or used in the formation of the outer mem-
brane trehalose dimycolates (TDMs, cord factor) (Figure 3). Theogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 77
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target by detailed characterization of an Ag85C-binding mole-
cule, 2-amino-6-propyl-4,5,6,7-tetrahydro-1-benzothiophene-
3-carbonitrile (I3-AG85), that exhibits an antimycobacterial
activity toward M. tuberculosis growing both in vitro and within
macrophages (Warrier et al., 2012) by blocking Ag85-mediated
TDM synthesis with no effect on covalently linked MAs.
It appears therefore that the chemical and biological validation
as essential proteins and therapeutic targets of the key enzymes
in the MA pathway (InhA, HadABC, FadD32, Pks13, MmpL3.)
opens an important avenue for the development of antituber-
cular drug discovery. Additional lead compounds need to be
identified to compensate for high attrition rates in drug discovery
pipelines and to counteract the continuing emergence of drug
resistance. Also, design and synthesis of derivatives of validated
drugs with improved anti-TB potency and pharmacokinetic
properties represent additional promising approaches.
MA Patterns and Packing into the Cell Wall
MAs possess unique characteristics essential for their physio-
logical roles in maintaining the cell wall structure of mycobacte-
ria. The importance of the MAs in the formation of the cell wall
permeability barrier was known long ago. Mycobacteria are
extremely impermeable to hydrophilic molecules, including anti-
biotics and nutrients such as glucose and glycerol (Jarlier and
Nikaido, 1990). This low permeability was correlated with the
extremely hydrophobic surface attributed mainly to the high
amounts of MAs in the cell wall (Figure 1).
In the early 1980s, Minnikin (1982) proposed that MAs are
assembled as a monolayer with their very-long chains parallel
to one another. The alkyl chains of other lipids would intercalate
between the long mero-chain and a branch chain of mycolates,
with the whole structure forming an asymmetrical bilayer that
would form a barrier to hydrophilic molecules (Figure 1). Support
of this hypothesis came from freeze fracture experiments that
showed two fracture planes of weakness in the mycobacterial
envelope: (1) the plasma membrane, as expected, and (2) the
cell wall (Barksdale and Kim, 1977). Furthermore, X-ray diffrac-
tion measurements of purified envelopes showed a strong
reflection at 4.2 A˚, distinctive of ordered fatty acyl chains, and
a diffuse reflection at 4.5 A˚, indicating a less ordered region
(Nikaido et al., 1993). That the molecules involved are mycolates
was demonstrated bymeasuring the ‘‘melting point’’ of cell walls
purified frommycobacterial species of variousmycolate compo-
sitions by differential scanning calorimetry (George et al., 1995;
Liu et al., 1995, 1996). The occurrence and configurations of
the double bonds and cyclopropyl groups as well as the lengths
of theMAs are important for the observed phase changes. Deter-
mination of the fine structure of how mycoloyl residues are
attached to the pentaarabinosyl termini of AG (McNeil et al.,
1991) further explained the existence of a mycolate monolayer
despite their attachment to the polysaccharide.
The importance of the fine structure of MAs was illustrated by
studying the conformational behavior of different types of MAs
by Langmuir monolayers experiments. According to the types
of MAs, a or oxygenated, folded or extended conformations
were adopted, depending on temperature (Villeneuve et al.,
2005). Double bonds or cylopropane rings are regularly spaced,
around 14–17methylene units, andmethyl branches are found at78 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rboth proximal and distal positions adjacent to the double bonds.
It has been previously demonstrated that the regular spacing of
functional groups in mycobacterial MAs facilitates folding and
packing in monolayer studies (Villeneuve et al., 2005, 2007).
This folding ability is important in allowing MAs to be accom-
modated within the dimensions of the mycobacterial outer
membrane (Figure 1), whose thickness is surprisingly conven-
tional as revealed by cryo-electron microscopy (Hoffmann
et al., 2008; Zuber et al., 2008).
Some Biological Properties of MAs
M. tuberculosis is an obligate human parasite able to develop
in alveolar macrophages. The persistence for decades in the
human host, thus resisting to an active immune response, is
a characteristic of the resulting disease. It takes 6 months
and four drugs to treat uncomplicated TB. Infection with
M. tuberculosis gives rise to granulomatous inflammation at
infection site and a powerful induction of T cell responses.
The existence of mycobacterial components with substantial
immunostimulatory activity is furthermore reflected in the prom-
inent activity of Freund’s complete adjuvant based on mineral
oil formulated with heat-killed mycobacteria. Immunostimula-
tory activity of lipids associated with the mycobacterial cell
wall has been recognized for several decades and has been ex-
ploited in a large variety of different adjuvant preparations, such
as the Ribi systems where the corynebacterial TDM analog rep-
resents one of the key constituents. Several compounds from
the mycobacterial cell wall have been implicated in mediating
host cell immune activation, including lipids that constitute up
to 40% of the dry weight of the cell envelope. Several aspects
of the biological activities of MAs have been reviewed previ-
ously (Barry et al., 1998; Vergne and Daffe´, 1998; Verschoor
et al., 2012).
Immunostimulatory Activity of MA-Containing
Compounds
The first observation concerning the virulence of
M. tuberculosis was the formation of ‘‘cords’’ under suitable
conditions in vitro. By treating the living virulent bacilli with pe-
troleum ether, this characteristic was lost and the virulence was
reduced (Bloch, 1950); the solvent-extracted compound was
identified as a-a’, trehalose 6-60 dimycolate or TDM (formerly
known as ‘‘cord factor’’) as the principal biologically active lipid
from mycobacteria (Noll et al., 1956). TDM protects the bacilli
within macrophages by reducing antibiotic effectiveness and
inhibiting the stimulation of protective immune responses.
Numerous other roles have been associated with TDM, greatly
depending on the ways of mixing the glycolipid with other lipids
(Vergne and Daffe´, 1998). These roles include the inhibition of
phagosome-lysosome fusion and acidification of phagosomes
(Indrigo et al., 2002, 2003) and tissue damage and necrosis
(Hunter et al., 2009) by inducing a high level of the proinflamma-
tory cytokines tumor necrosis factor alpha, interleukin-6 (IL-6),
and IL-12 when used for stimulation of bone marrow dendritic
cells.
To achieve its survival inside macrophages, M. tuberculosis
establishes chronic infection characterized by the formation of
granulomas, whose production has been reproduced by purified
TDM. Recently, this glycolipid has been shown to activate the
Syk-Card9 signaling pathway in macrophages through bindingights reserved
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is required for activation of macrophages by TDM in vitro and for
granuloma formation in vivo after injection of TDM (Lang, 2013). It
is not known, however, whether this pathway is also exploited by
M. tuberculosis to transform the macrophage into a comfortable
niche.
The adjuvant activity of the mycobacterial lipid extract from
M. bovis BCG lipid extract was shown to be also attributable
to glycerol monomycolate, delivered in cationic liposomes, that
was particularly efficient in T helper 1-inducing adjuvant formula-
tion effective against TB. This mycobacterial antigen stimulates
CD1b-stimulated CD4+ T cells, and both the hydroxyl group of
glycerol and the MA lengths were shown to be critical for trig-
gering the T cell responses. The stereochemistry of the mole-
cule, e.g., the (R)-1-O-mycoloyl-glycerol was more stimulatory
than the (S)-1-O-mycoloyl-glycerol, as well as the chain lengths
of MA were found to play an important role in T cell responses
(Layre et al., 2009). Similarly, in free MAs and glucose monomo-
nomycolate (GMM) presented on CD1b-restricted T cells, the
precise structures of natural GMM, including the glucose, the
linkage of the glucose to the MA, and the R,R-stereochemistry
of the hydroxyl part of the mycolate, have been shown to dictate
the T cell recognition (Moody et al., 1997, 2000).
Although immunological properties have been described for
chemical structures related to the AG termini (Rombouts et al.,
2012; Watanabe et al., 1999), these may occur only after the
killing and degradation of the bacilli.
MA Types and Virulence
In M. tuberculosis and species that form the complex a-, keto-,
and methoxy-MAs are the main classes of MAs, except some
M. bovis BCG strains where methoxymycolates may be absent
(Daffe´ et al., 1982). The three classes of MA are found in all the
MA-containing compounds. The different types of MAs may
differ in their ability to attack neutrophils, induce FMs, or adopt
an antigenic structure for antibody recognition, depending on
the chemical functions decorating the meromycolic chain, cis/
trans-cyclopropanes, and oxygenated groups.
TB is characterizedbya tight interplay betweenM. tuberculosis
bacilli and host cells within granulomas. Accumulation of lipid
droplets in the macrophages of individuals developing a postpri-
mary infection gives the foamy aspect to these macrophages. In
alveolar FMs, the bacilli were mainly found within lipid droplets.
These cellular aggregates restrict bacterial spreading but do
not kill all the bacilli, and they can persist for years (Russell,
2007). The formation of FMs, a granuloma-specific population
characterized by its high lipid content, was studied compara-
tively in mycobacteria with different MA composition, i.e.,
M. tuberculosis, M. smegmatis, and a transformant strain of the
latter species overexpressing the hma gene and responsible for
the introduction of keto-mycolic acids in the strain. Only bacteria
containing oxygenated MAs induced the formation of FMs.
Oxygenated MAs triggered the differentiation of human mono-
cyte-derived macrophages into FMs that could constitute a
shelter for persisting bacilli (Peyron et al., 2008). Using the hma-
deleted mutant strain, oxygenated MAs have been shown to be
necessary for the virulence of M. tuberculosis in mice (Dubnau
et al., 2000). Similarly, cycolopropanation ofa-MAat theproximal
position was shown to impact both the formation of ‘‘cords’’ and
the virulence of the tubercle bacilli (Glickman et al., 2000). Trans-Chemistry & Biolcyclopropanation of MAs on trehalose dimycolate has been
shown to suppress M. tuberculosis-induced inflammation and
virulence (Rao et al., 2006).
MAs and Biofilm Formation
A biofilm is defined as a structural community of bacteria en-
closed in a self-produced polymeric matrix and adherent to an
inert or living surface. Biofilms are strongly implicated in chro-
nicity and transmission of several infections. M. tuberculosis is
able to form biofilms, and this property was exploited long ago
for the production of cell biomasses necessary to chemically
characterize the constituents of the bacterial cells. Indeed, his-
torically, M. tuberculosis was grown as a surface pellicle, a bio-
film-like structure, at the liquid-air interface in some synthetic
media, notably on Sauton medium. Several other mycobacteria
have been shown to form biofilms with implications for their sur-
vival (Nyka, 1974; Smeulders et al., 1999). These in vitro myco-
bacterial biofilms were shown to be rich in free MAs released
either from enzymatic hydrolysis of TDM or after cell lysis due
to long-time culture (Ojha et al., 2010). Biofilm formation is also
associated with increased synthesis of C56–C58 FAs (Ojha
et al., 2005). A correlation between MA biosynthesis and biofilm
formation has been demonstrated by inactivation of the groEL1
gene, a dedicated chaperone involved in MA biosynthesis.
GroEL1 modulates synthesis of MAs specifically during biofilm
formation and physically associates with the ketoacyl-ACP syn-
thase KasA. In the same context, the deletion of cpn60.1 (also
known as hsp60 or groEL) in M. bovis BCG led to loss of the
capacity to form a biofilm, accompanied by changes in lipid
composition, mainly MAs (with two to four carbon atoms shorter)
and phthiocerol dimycocerosates (Wang et al., 2011). Expect-
edly, the reduction in the mycolate chain length caused by the
deletion of kasB also impacts biofilm formation (Gao et al., 2003).
The types of MAs also play a role in biofilm formation, as typi-
fied by the essentiality of the keto-mycolic acids in these struc-
tures. By deletion ofmmaA4 (or hma) gene, the resulting mutant
devoid of keto-mycolic acid was shown to be both pellicle-
defective and highly sensitive to rifampicin under planktonic
growth. It was proposed that when incorporated within the
wild-type pellicle biofilm, the cells were protected from the
bactericidal activity of the antibiotic (Sambandan et al., 2013).
Concluding Remarks and Perspectives
In the past decades, extensive efforts have been devoted to
deciphering the biosynthesis pathway leading to MAs, a reser-
voir of new targets urgently needed to fight MDR and XDR tuber-
cle bacilli strains. Novel, promising drug candidates targeting the
MA biosynthesis and other pathways are in the pipeline, espe-
cially with the current use of whole-cell screening in addition to
the more conventional target-based HTS strategy. This does
not mean, however, that the whole biosynthesis is fully known
and in detail. Many relevant questions remain to be solved.
Some of these questions are presented below.
(1) Is FAS-II the system that carries out the elongation of the
acyl chains in vivo until reaching the full-length ‘‘meromy-
colates’’? Actually, FAS-II has been shown to elongate
C12–C16 FAs to yield C18–C30 acyl-ACPs in vitro (Odrio-
zola et al., 1977), which are most likely the precursors
of the very long-chain ‘‘meromycolic’’ acids. The in vitroogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 79
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nents for longer chain acyl thioester substrates (KasA,
KasB, MabA, InhA, and HadABC) supports this functional
differentiation. Based on the in vitro studies, the FAS-II
ketoacyl synthases (KasA and KasB) and the hydroxyacyl
dehydratases (HadABC) are involved, with distinct chain
length specificities, in the subsequent elongation of
AcpM acyl thioesters to C40 and C54 carbon chains,
respectively (Schaeffer et al., 2001; Slayden and Barry,
2002). Even though FAs of up to C50 have been shown
to be synthesized in cell-free extracts (Qureshi et al.,
1984), the extension of C18–C30 to C50–C60 carbon acyl
chains by FAS-II have not been demonstrated formally.
(2) Are the elongation/desaturation/modifications that char-
acterize the mature ‘‘meromycolic’’ acid occurring on
the growing chain? In M. tuberculosis, the characteriza-
tion of monounsaturated FAs ranging from C24 to C30
with a double bond localized exactly at the position ex-
pected for the elongation of a D5 tetracosenoic acid pre-
cursor (Asselineau et al., 1970a) suggests that at least
some of the modifications are introduced during the
growth of the meromycolic chain (Takayama and Qureshi,
1978); a report in favor of this hypothesis has been also
published (Yuan et al., 1998). Nevertheless, conclusive
data proving that these modifications are introduced
either in the completed MAs or at an earlier stage in their
synthesis are still lacking.
(3) Which genes encode the proteins dedicated to the desa-
turation/isomerization during the biosynthesis of MA?
In mycobacteria, all mycolates have two positions, i.e.,
distal and proximal, that initially contain double bonds,
subsequently modified into cis-cyclopropane, trans dou-
ble bonds, cyclopropane, epoxide, or hydroxyl with an
adjacentmethyl branch. The proteins catalyzing these de-
saturation/isomerization steps, as well as the underlying
mechanisms, remain to be discovered and studied.
(4) Is the biosynthesis ofMAs a tightly regulated process, and
if so, when and how? The activities of several enzymes
of the M. tuberculosis FAS-II system, e.g., KasA, InhA,
MabA, HadAB, and HadBC, have been shown to be
downregulated by phosphorylation (Molle and Kremer,
2010), a growth phase-dependent phenomenon (Slama
et al., 2011). However, the genes regulating this process,
the timing and its consequences on the bacterial physi-
ology are unknown.
(5) The discovery of the MA biosynthesis regulator MabR
raises several important questions concerning how this
regulator is used by bacterial cells for adaption to their
environment. A key advance will be the identification of
the ligand(s) that control DNA-binding properties of this
factor. It is likely that MabR may control a broader set of
genes in addition to those identified previously (Salzman
et al., 2010). In addition, a global analysis of the MabR
regulatory activity may provide the answers to why this
transcriptional regulator is essential for mycobacterial
survival.
(6) Is the production of MAs coordinated with its transport to
the cell wall? To which compartment? Our group has
provided data on protein-protein interactions betweenChemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All righknown FAS-II enzymes (Veyron-Churlet et al., 2004,
2005), and with MA MTs (Cantaloube et al., 2011).
Accordingly, we have proposed a working model with
different specialized FAS-II complexes that would be in-
terconnected and interact. The resulting meromycolic
acid will be condensed to yield the b-keto precursor of
MAs. This synthesis is very likely to occur in the cytosol
and MAs have to be transported to the mycomembrane
and beyond. Recently, MmpL3 was identified as the
transporter of TMM through the plasma membrane
(Grzegorzewicz et al., 2012b). Where these proteins
are localized and whether they are clustered have to
be experimentally established. Our unpublished data
(C. Carel, K. Nukdee, S. Cantaloube, M. Bonne, C.T.
Diagne, F. Laval, M. Daffe´, and D. Zerbib) suggest that
the different players in the biosynthesis of MAs are
located at the bacterial poles.ACKNOWLEDGMENTS
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